» Articles » PMID: 30278439

LncRNA AFAP1-AS1 Promotes Migration and Invasion of Non-Small Cell Lung Cancer Via Up-Regulating IRF7 and the RIG-I-Like Receptor Signaling Pathway

Overview
Date 2018 Oct 3
PMID 30278439
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: Accumulating evidence has highlighted the importance of long non-coding RNAs (lncRNAs) as competing endogenous RNAs (ceRNAs) in tumor biology. Among others, actin filament-associated protein 1 antisense RNA 1 (AFAP1-AS1) has been associated with non-small cell lung cancer (NSCLC). However, it remains unclear how AFAP1-AS1 participates in the development and progression of NSCLC.

Methods: The peripheral blood samples were collected from patients with NSCLC. White blood cell subsets were classified and levels of interleukin (IL)-10, IL-12 and IFN-γ in serum were measured. We then identified its target gene of AFAP1-AS1 via bioinformatics methods. NSCLC cell line with the highest expression of AFAP1-AS1, i.e. H1975 was selected for in vitro experiments. A series of inhibitor, vector and siRNA were employed to validate the regulatory mechanisms of AFAP1-AS1 in the development and progression of NSCLC. Cell proliferation was detected by MTT assay and EdU staining. Cell migration and invasion, and cell cycle and apoptosis were measured by transwell assay and flow cytometry, respectively.

Results: A high expression of AFAP1-AS1 was identified in NSCLC, alongside with a reduced level of IL-12 and increased levels of IL-10 and interferon (IFN)-γ. Aberrant expressions of AFAP1-AS1 were associated with pathological grade, TNM staging and metastatic potential of NSCLC. AFAP1-AS1 could activate interferon regulatory factor (IRF)7, the retinoid-inducible protein (RIG)-I-like receptor signaling pathway and Bcl-2 in vitro. Over-expression of AFAP1-AS1 promoted NSCLC cell proliferation, invasion and migration while inhibiting cell apoptosis.

Conclusion: lncRNA AFAP1-AS1 promotes migration and invasion of non-small cell lung cancer via up-regulating IRF7 and the RIG-I-like receptor signaling pathway.

Citing Articles

Pharmacogenomic and epigenomic approaches to untangle the enigma of IL-10 blockade in oncology.

Elemam N, Mekky R, Rashid G, Braoudaki M, Youness R Expert Rev Mol Med. 2024; 26:e1.

PMID: 38186186 PMC: 10941350. DOI: 10.1017/erm.2023.26.


Integrated multi-omics analysis for lung adenocarcinoma in Xuanwei, China.

Jiang B, Yang J, He R, Wang D, Huang Y, Zhao G Aging (Albany NY). 2023; 15(23):14263-14291.

PMID: 38095636 PMC: 10756121. DOI: 10.18632/aging.205300.


Circulating noncoding RNAs: promising biomarkers in liquid biopsy for the diagnosis, prognosis, and therapy of NSCLC.

Li Y, Ye J, Xu S, Wang J Discov Oncol. 2023; 14(1):142.

PMID: 37526759 PMC: 10393935. DOI: 10.1007/s12672-023-00686-3.


A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.

Yu S, Tang L, Zhang Q, Li W, Yao S, Cai Y Hereditas. 2023; 160(1):31.

PMID: 37482612 PMC: 10364405. DOI: 10.1186/s41065-023-00293-w.


Long Non-Coding RNAs as Emerging Targets in Lung Cancer.

Gencel-Augusto J, Wu W, Bivona T Cancers (Basel). 2023; 15(12).

PMID: 37370745 PMC: 10295998. DOI: 10.3390/cancers15123135.